A world-leading hub for expertise in neurodegenerative disease diagnostics
Little by little, and day by day, neurodegenerative diseases like Alzheimer’s and Parkinson’s slowly steal people’s lives. Families watch, helpless, as loved ones sadly slip away. It must be one of humankind’s highest priorities to tackle these withering conditions. To do so would be a testament to our determination, our compassion and the values that make us who we are.
The Fujirebio Neuro Center of Excellence has been founded with the objective of rising to this challenge. It is a research and development hub focused on developing diagnostic solutions to these debilitating diseases. It is intended as a knowledge-sharing meeting point between Fujirebio’s expert teams in Europe, Japan and USA, and neuro professionals worldwide. But more than this, it is a catalyst for collaborations and partnerships with a broad range of stakeholders, including routine laboratories, OEMs, pharma companies, clinicians, researchers and academia. Above all, it is a ray of hope for patients, families and caregivers.
But why Fujirebio and why now? Through its acquisition of Innogenetics, Fujirebio has an unrivalled heritage as a pioneer in the field of Alzheimer’s research, and today laboratories all around the world depend on its ground-breaking biomarkers and automated testing systems.
Key milestones in the company’s involvement with Alzheimer’s include:
- the launch in 1995 of the world’s first commercialized biomarker for early detection of the plaques associated with Alzheimer’s on the INNOTEST® platform.
- the launch in 2005 of plasma-based biomarkers on the INNO-BIA platform.
- and most recently in 2018, for the first time ever, the ability to perform the four most important neurodegeneration parameters on a single fully automated CLEIA platform (LUMIPULSE® G).
The desire to tackle neurodegenerative diseases runs deep throughout our team. The profound historical knowledge of the disease that is rooted in Fujirebio supports our progress in delivering promising new testing techniques, such as plasma-based diagnostics tests for Alzheimer’s disease.
The center builds on a culture of insatiable curiosity that has made Fujirebio a world leader in neurodegenerative disease diagnostics and a pioneering developer of a wide range of IVD testing solutions. Its doors are open to all participants in the race to find the next generation of diagnostics and therapeutics. This is a center for partnership and collaboration, a place for research, development and manufacture, a meeting place for brilliant minds and a starting point for great ideas.
Our doors are open - contact us
We encourage partnerships dedicated to advancing neurodegeneration diagnostics.